GB Pant 1st year DM Cardiology resignation exposes harsh realities of endless duties

New Delhi: A letter from a concerned wife to one of the most prestigious cardiology hospitals in Delhi, GB Pant Hospital, asking the authority to intervene with the cooling period from prolonged working hours and counselling for her husband, a first-year DM Cardiology student, has once again brought the plight of the Indian resident doctors into light.

The recent letter of Dr. Rishu Sinha, the wife of a first-year DM Cardiology resident, Dr Amit Kumar, has gone viral in the medical circle, with many doctors on social media empathising and sharing the broader concerns faced by the resident doctors- especially their mental breakdown caused by prolonged duty hours compromising sleep and rest.

In the letter addressed to the Cardiology Department of GB Pant Hospital, Dr. Sinha mentioned how her husband, Dr. Kumar, took the extreme step of resigning from a dream job- a superspeciality course of cardiology, primarily due to excessive work pressure and duty hours.

“My Husband, Dr. Amit Kumar, pursuing DM in Cardiolog,y is suffering from sleep deprivation, burnout, exploitation and humiliation due to 36 hours continued duty causing mental and physical tiredness as well forced for minimal work not suitable for his course. Due to such toxicity and depression, he has submitted his resignation on 23.10.2025. The National Task Force Report 2024 is also concerned with the mental health problems of the medical students due to excessive working hours. Therefore, GB Pant Hospital shall must take responsibility of the outcome of the excessive duty hours and ensure wellness of the students,” Dr. Sinha’s letter mentioned.

Mentioning how pursuing the Super Speciality course in Cardio was her husband’s lifetime dream, Dr. Sinha further added, “But he has been forced to resign due to excessive, unauthorised and illegal working hours.”

She asked the Department for a cooling period and proper counselling before accepting the resignation of her husband and wrote, “I am worried that if the resignation is accepted without his proper counselling, it may further harm his mental health. Therefore, I request to provide him humanly working hours duty for one month as cooling period and proper counselling before accepting his resignation. It may help him to come out from the trauma faced by him since joining the course.”

This is not the first time that the excessive duty hours violations at the workplace have been highlighted. Recently, a nationwide survey was conducted by the United Doctors Front (UDF), and the Medical Dialogues team gathered responses from 1,031 medicos across India, and it revealed that 62% of the respondents reported working for more than 72 hours per week, while more than half said that they do not receive a weekly off. A whopping 86% of the respondents expressed their belief that excessive duty hours are directly harming their mental health and compromising patient safety.

1992 Residency Rules: 

Reasonable working hours have been a long-pending demand of the resident doctors. Medical Dialogues had earlier reported that after the Supreme Court took cognisance of the issue, the Central Government introduced the Central Residency Scheme, 1992.

Addressing the issue of duty hours of resident doctors, the scheme said that continuous active duty for resident doctors will not normally exceed 12 hours a day and subject to the exigencies of work, the residents will be allowed one weekly holiday by rotation.

However, these rules only remained on paper, and the plights of resident doctors continue till now. Earlier this year, the United Doctors’ Front (UDF) filed a Public Interest Litigation (PIL) in the Supreme Court against the “inhumane working hours of resident doctors”. The association has challenged the “exploitative and unconstitutional working conditions imposed on resident doctors across the country”.

Amid all this, the allegations made by Dr. Sinha regarding the prolonged working hours faced by her husband while pursuing the DM Cardiology course at GB Pant Hospital have highlighted the reality of the resident doctors once again.

RTI Applications:

Dr. Sinha has already filed two Right to Information (RTI) applications before the hospital, seeking information regarding the working hours rules as well as the duty performed by Dr. Amit Kumar.

“I had also sought information regarding implementation of 1992 directives (48 hours a week and maximum 12 hours at a stretch). But I was not supplied any information despite both of my RTI were under 48 hours provisions of RTI Act. This is unfortunate that the institutions like GB Pant Hospital have no faith in law of the land as 1992 rules are not followed and RTI Act is not honoured at all. How can an legal entity ingnore the rules and acts applied to them?” Dr. Rishu Sinha’s letter addressed to the Cardiology Department mentioned.

Speaking to Medical Dialogues, Dr. Sinha said, “Because of toxic duty hours and inhumane activity, he was forced to resign the day before yesterday. For the four months, he was working 36 hours duty at a stretch, which is very inhumane without any support and rest. He has worked really hard for the seat, to crack NEET-SS exam and it was his passion to pursue the degree, but because of the mental trauma and working health condition and toxicity in the college, has broken him so much that he decided to quit.”

“I have filed an RTI to GB Pant two times. Even after 30 days of mandatory reply, they didn’t give a single reply and they are just silent on the matter. So, he lost the hope and he gave resignation,” she added.

Referring to the 1992 rules regarding the duty hours of doctors, Dr. Sinha added, “Is anyone above the law? Why are you not following the law which is already there? Why should a doctor have to compromise between profession and health? What about the mental health of the doctors? They are not machines and what kind of quality treatment will they give to the patients?

“My husband is a very good doctor. He has done MD Medicine and got All India Rank 2,” said Dr. Sinha, further questioning that if doctors like him, who are capable of providing very good treatment to the patients, leave their seats, how will it affect the healthcare system? 

Dr. Sinha has found support from the medical bodies. Expressing concern over the issue, the Delhi Medical Association (DMA) mentioned how such “pathetic and inhumane” working hours being imposed on resident doctors across institutions “only compromise their well-being but also affect the quality of healthcare delivery.”

The association has also forwarded the letter received from Dr. Sinha to the Director of the Directorate of Health Services, Delhi, for taking the necessary action.

Dr. Sinha informed Medical Dialogues that she plans to approach the Hospital in person to raise the matter. She also indicated that she might have to take legal recourse if her pleas go unheard.

Powered by WPeMatico

CDSCO Flags Besto-Cof Cough Syrup as Spurious, Raipur Drug Lab Claims Batch Not Made by Listed Firm

New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has issued a warning after the State Drug Testing Laboratory (SDTL) in Raipur, Chhattisgarh, flagged the widely sold ‘Besto-Cof Dry Cough Formula’ as potentially spurious. The batch details are currently under investigation, with the manufacturing and expiry dates unavailable.

According to the report, the manufacturer listed on the product label is under scrutiny, and the firm claiming to produce the drug has confirmed that the batch in question was not manufactured by them, strongly suggesting it is a spurious product. The product was identified during routine testing, and its sale and distribution pose a potential risk to consumers.

Besto-Cof Dry Cough Formula is a syrup used to relieve dry, hacking coughs and symptoms of the common cold and allergies. It is manufactured by Bestochem Formulations India Ltd. The medication combines a cough suppressant, an antihistamine, and a decongestant.

In accordance with the Drug and Cosmetic Act, a drug shall be deemed to be spurious—

(a) if it is imported under a name which belongs to another drug; or

(b) if it is an imitation of, or a substitute for, another drug or resembles another drug in a manner likely to deceive or bears upon it or upon its label or container the name of another drug unless it is plainly and conspicuously marked so as to reveal its true character and its lack of identity with such other drug; or

(c) if the label or the container bears the name of an individual or company purporting to be the manufacturer of the drug, which individual or company is fictitious or does not exist; or

(d) if it has been substituted wholly or in part by another drug or substance; or

(e) if it purports to be the product of a manufacturer of whom it is not truly a product

The term “Spurious Drug” has been defined under Section 17-B of the Drugs and Cosmetics Act, 1940

Medicines Flagged as Spurious

S.No

Name of Product

Batch No

Manufacturing Dates

Manufacturer Details

Reporting Source

Reporting by Lab/State

Reporting Month & Year

Remarks

1

Besto-Cof DRY COUGH FORMULA

NA

Manufacturing Date: N/A

Expiry Date: N/A

Manufacturer Name: Under Investigation Manufactured By: Under Investigation

State lab

SDTL Raipur, Chhattisgarh

SEP-2025

NSQ Remark: The product is purported to be spurious, however, the same is subject to outcome of investigationFirm Reply: The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug.

Powered by WPeMatico

Ruckus at Lucknow hospital over alleged negligence, Ayushman Bharat fraud

Lucknow: Tension erupted at a private superspeciality hospital in Vrindavan Yojna, Lucknow, after the family of a patient accused the hospital of performing an incomplete surgery and misleading them under the Ayushman Bharat Yojana scheme. The patient’s relatives created a ruckus on the hospital premises, alleging medical negligence and financial misconduct. 

Following the incident, the family lodged a formal complaint at the PGI police station, demanding a thorough investigation into the matter. 

Also Read:Varanasi Hospital sealed over alleged Ayushman Bharat Fraud

According to the complaint, the patient— a resident of Karaiya Baghi Bazaar, Gopalganj, Bihar, had been diagnosed at PGI Lucknow with three blocked arteries, for which doctors had advised bypass surgery. The family, after initial consultation, took the patient home but returned to Lucknow when his condition worsened.

Virendra Kumar Mishra, a relative of the patient, stated that the family later brought the patient to a private superspeciality hospital in Vrindavan Yojna after he experienced breathing difficulties. The hospital allegedly informed them that treatment would be covered under the Ayushman Bharat Yojana, with Rs 1.82 lakh to be deducted from the government scheme. However, the family was told to deposit an additional Rs 1 lakh in cash before surgery.

After the procedure, the family claimed they were told that only one of the three blocked arteries had been treated, rather than the full bypass surgery initially promised. When they protested, the hospital administration and the doctor allegedly misbehaved, abused, and threatened them.

This angered the family. Virendra Kumar Mishra filed a complaint at the PGI police station. The police said they will investigate the matter and send a letter to the CMO, reports Live Hindustan.

The incident has once again raised questions about oversight and transparency in private hospitals empanelled under government health schemes.

Also Read:Over 1,100 hospitals de-empanelled for AB-PMJAY Fraud: Health Minister tells Lok Sabha

Powered by WPeMatico

Sun Pharma Gets CDSCO Panel Approval to Conduct Phase III Study of Oral Semaglutide

New Delhi: Pharmaceutical major Sun Pharma Laboratories has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct the phase III clinical study to evaluate the efficacy and safety of oral Semaglutide tablets of Sun Pharma Laboratories in comparison to Rybelsus (Semaglutide) Tablets in Type 2 Diabetes Mellitus.

This came after the drug major Sun Pharma Laboratories presented the proposal to conduct Phase III clinical trial titled “A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral Semaglutide Tablets of Sun Pharma Laboratories Limited in Comparison to Rybelsus (Semaglutide) Tablets in Type 2 Diabetes Mellitus” as per Protocol Number-ICR/23/009, Version 2.0 dated 18.06.2025 along with the results of Bioavailability Study (SEM10524) conducted in India by the firm in India.

However, following a thorough review, the expert panel suggested to include Optical Coherence Tomography (OCT) as part of the eye examination. Furtermore, the committee stated that subjects with proliferative/unstable retinopathy and maculopathy to be excluded from the trial.

In addition to the above, the expert panel suggested that fasting and postprandial blood glucose monitoring should be used for dose titration and HbA1c levels should be assessed after completion of 08-12 weeks of study treatment.

Semaglutide is a glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults.

GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.

Semaglutide is 94% similar to human GLP-1. Analogs of this hormone such as semaglutide stimulate the synthesis of insulin by stimulating pancreatic islet cells and reducing glucagon secretion. They directly bind with selectivity to the GLP-1 receptor, causing various beneficial downstream effects that reduce blood glucose in a glucose-dependent fashion.

At the recent SEC meeting for endocrinology and metabolism held on 17th July 2025, the expert panel reviewed the proposal presented by Sun Pharma Laboratories to conduct Phase III clinical trial titled “A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral Semaglutide Tablets of Sun Pharma Laboratories Limited in Comparison to Rybelsus (Semaglutide) Tablets in Type 2 Diabetes Mellitus” along with the results of Bioavailability Study (SEM10524) conducted in India by the firm in India.

After detailed deliberation, the committee recommended grant of permission to conduct the Phase III clinical trial as per the presented protocol with the following changes:

1. Inclusion of Optical Coherence Tomography (OCT) as part of the eye examination.

2. Subjects with proliferative/unstable retinopathy and maculopathy to be excluded from the trial.

3. Fasting and postprandial blood glucose monitoring should be used for dose titration. HbA1c levels should be assessed after completion of 08-12 weeks of study treatment.

In line with the above, the expert panel suggested the firm to submit revised protocol to CDSCO for further evaluation.

Powered by WPeMatico

UP NEET counselling 2025 round 3 schedule revised, choice filling till October 27th, check details

Uttar Pradesh: The Directorate General of Medical Education and Training (UPDGME), Uttar Pradesh, has revised the UP NEET UG round 3 Counselling for the academic year 2025 for MBBS and BDS admissions under the state quota in government and private medical and dental colleges across the state.

According to the revised schedule, the online choice-filling process will now be conducted till October 27, 2025, 11:00 AM.

The seat allotment results are scheduled to be declared on October 29, 2025. Following this, the downloading of allotment letters and admission formalities will take place in two phases. Below is the detailed schedule-

REVISED SCHEDULE

S.NO

ACTIVITY

DATES

DURATION

1

Online choice filling.

Oct 17 (2:00 PM) – Oct 27 (11:00 AM).

10 Days

2

Allotment result declaration.

Oct 29, 2025.

1 Day

3

Downloading of allotment letters & admission.

Oct 30 – Nov.

6 Days

Meanwhile, it is to be noted that only those candidates will be eligible for choice filling who have completed the online registration process, whose original documents have been verified online, and who have deposited the required security amount.

To view the revised schedule, click the link below

https://medicaldialogues.in/pdf_upload/unconfirmed-721850crdownload-305589.pdf

Prior to this, UPDGME had released the Round 3 seat matrix for the NEET UG counselling for the academic year 2025. On this, Medical Dialogues has earlier reported that the seat matrix detailing the available MBBS and BDS seats across Government, Autonomous, and Private medical and dental colleges in the state.

The seat matrix includes updated seat availability under various categories, including Unreserved (UR), Other Backwards Classes (OBC), Scheduled Castes (SC), Scheduled Tribes (ST), and Economically Weaker Sections (EWS). As per the seat matrix, a total of 962 seats are vacant in the Medical and Dental colleges of UP. Of these, a total of 817 seats are va cant for MBBS and a total of 145 seats are vacant for BDS courses.

Powered by WPeMatico

BFUHS releases revised NEET counselling schedule, check details

Punjab: The Baba Farid University of Health Sciences (BFUHS) has revised the NEET UG 3rd Round Counselling 2025 for MBBS and BDS admissions across Punjab.

The revised schedule has been released on the official website of BFUHS. 

According to the revised schedule, the Processing of seat allotment will be done from today, i.e. 25th October 2025. Following this, the provisional allotment / Result will be displayed on 28 October 2025. Below is the detailed schedule-

REVISED SCHEDULE

S.NO

PARTICULARS

REVISED DATES

1

Date of Surrender/Resignation by Round-1 & 2 joined candidates with forfeiture of security deposit.

Upto 24 October 2025

2

Processing of seat allotment.

25 to 26 October 25

3

Display of provisional allotment / Result.

28 October 25

4

The last date/time of submission of objections to provisional allotment (if any) by the NEET UG aspirants.

29 October 2025, upto 03.00 PM

5

Display of revised provisional allotment/result after any change in provisional allotment due to objections (if any).

Upto 04 November 2025

6

The provisionally selected candidates will pay the balance amount of the fee (six-month fee after deducting the amount of the security deposit) through the university payment gateway available on the university website and will report to the respective college for joining in the respective allotted college.

04 to 05 November 2025

To view the revised schedule, click the link below

https://medicaldialogues.in/pdf_upload/bfuhs-revises-punjab-neet-2025-round-3-counselling-schedule-for-mbbs-bds-admissions-new-dates-announced-305597.pdf

ELIGIBILITY

1 The candidates who can apply afresh for the 3rd Round of counselling (These candidates have to pay the registration fee and security amount at the time of submission of willingness as per rules)

a) The candidates who will register/apply for the first time.

b) The candidates who have not joined the allotted seat (fresh/upgraded) of Round-II counselling can apply afresh for 3rd Round and they will have to deposit the security amount again for submitting willingness and choices/preferences of Course/College/Quota as per the schedule.

Powered by WPeMatico

FDA approves nonhormonal drug to ease menopause hot flashes and night sweats

The federal Food and Drug Administration today approved a new menopause drug that reduces hot flashes and night sweats after the drug was successfully tested at UVA Health and other sites in the United States and around the world.

Powered by WPeMatico

FDA approves nonhormonal drug to ease menopause hot flashes and night sweats

The federal Food and Drug Administration today approved a new menopause drug that reduces hot flashes and night sweats after the drug was successfully tested at UVA Health and other sites in the United States and around the world.

Powered by WPeMatico

Certain viral combinations raise risk of severe respiratory illness in infants

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral combinations dramatically increase the risk of severe disease. The findings, published this month in Journal of Infection, come from the Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes (PRIMERO), which followed more than 2,000 children from birth to age two between 2020 and 2024.

Powered by WPeMatico

Certain viral combinations raise risk of severe respiratory illness in infants

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral combinations dramatically increase the risk of severe disease. The findings, published this month in Journal of Infection, come from the Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes (PRIMERO), which followed more than 2,000 children from birth to age two between 2020 and 2024.

Powered by WPeMatico